Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: Association of the triglyceride–glucose index with the severity of lower extremity arterial disease across glucose metabolic states: a single-center cross-sectional study of 656 patients with angiographically confirmed disease

Date Published: 2026-10-23

Abstract:
To examine the cross-sectional association between the triglyceride–glucose (TyG) index and the severity of lower extremity arterial disease (LEAD) in hospitalized patients with angiographically confirmed LEAD, to test whether this association differs across Glucose Metabolic States, and to quantify the ability of the TyG index to discriminate prevalent ischemic tissue loss (Rutherford grades 5–6). This single-center, retrospective, cross-sectional study included 656 consecutive patients with angiographically confirmed LEAD who were hospitalized in the Department of Vascular Surgery at the General Hospital of Ningxia Medical University from January 2023 through December 2024. Diagnosis was confirmed by digital subtraction angiography (DSA). Patients were classified into four groups according to their Glucose Metabolic States: normal glucose tolerance (NGT, n = 150), impaired glucose regulation (IGR, n = 148), diabetes with a duration of <10 years (DM<10y, n = 174), and diabetes with a duration of ?10 years (DM?10y, n = 184). Glucose and lipid parameters and LEAD severity (Rutherford classification) were assessed during the same hospitalization. Spearman correlation, multinomial logistic regression (with grade 1 mild claudication as the reference), ordinal logistic regression with a TyG × Glucose Metabolic States interaction term, proportional-odds assessment by cumulative binary splits, ROC analysis with bootstrap internal validation (1,000 resamples), and decision-curve analysis were performed. Sensitivity analyses used continuous glycemic measures instead of the categorical groups, excluded implausibly low fasting glucose values, and added liver enzymes to the adjustment set. The primary outcome was ischemic tissue loss, defined as Rutherford grades 5–6 (n = 205, 31.2%). The TyG index increased progressively across Glucose Metabolic States categories (8.79 ± 0.51, 9.15 ± 0.48, 9.57 ± 0.56, and 9.67 ± 0.52 for NGT, IGR, DM < 10 years, and DM ? 10 years, respectively; P < 0.001) and was strongly correlated with Rutherford grade (Spearman r = 0.677, P < 0.001). In a multinomial logistic regression model adjusted for age, sex, smoking, hypertension, BMI, and fatty liver disease (all variance inflation factors < 1.5), the TyG index remained associated with each severity category above the reference, with adjusted odds ratios per 0.5-unit increment of 2.51 (grade 2), 2.83 (grade 3), 7.56 (grade 4), 9.62 (grade 5), and 20.45 (grade 6). The interaction between TyG and Glucose Metabolic States was statistically significant (likelihood-ratio ?² = 95.63, df = 3, P < 0.001); stratum-specific odds ratios per 0.5-unit increment were 1.51 (95% CI 1.07–2.13) in IGR, 2.50 (1.90–3.29) in DM < 10 years, and 8.14 (5.23–12.67) in DM ? 10 years, whereas the NGT-stratum estimate was unstable (quasi-complete separation) and could not be interpreted. When the categorical groups were replaced with a continuous glycemic measure, the interaction with fasting plasma glucose remained significant but was in the opposite direction (?² = 9.36, df = 1, P = 0.002): the TyG–severity association was stronger at lower fasting glucose levels (OR per 0.5 unit 4.81 at 4.8 mmol/L) than at higher fasting glucose levels (3.46 at 8.3 mmol/L). For discriminating Rutherford grades 5–6, the AUC was 0.833 (95% CI 0.796–0.870); the Youden-optimal cutoff was 9.42 (sensitivity 85.9%, specificity 71.0%, positive predictive value 57.3%, negative predictive value 91.7%, LR + 2.96, LR? 0.199), and this cutoff was stable across bootstrap resamples. Decision-curve analysis showed a positive net benefit relative to treat-all or treat-none strategies across threshold probabilities of approximately 0.09–0.57. In this cohort of patients with angiographically confirmed LEAD, the TyG index was independently associated with LEAD severity. The strength of this association appeared to vary across Glucose Metabolic States, but the apparent gradient from normal glucose tolerance to long-standing diabetes was not reproduced when glucose was modelled continuously, suggesting that part of the categorical pattern is attributable to the grouping itself (i.e., mathematical coupling and range restriction). The TyG index showed moderate ability to discriminate prevalent ischemic tissue loss. Because exposure and outcome were assessed during the same hospitalization, these findings represent a cross-sectional association rather than a predictive one; the proposed cutoff values were derived from the same sample in which they were evaluated and require external validation before they can be considered for clinical use.

Introduction:
The triglyceride–glucose (TyG) index, calculated from fasting plasma glucose and triglyceride concentrations, is a simple surrogate marker of insulin resistance. Unlike the homeostasis model assessment of insulin resistance (HOMA-IR) and the hyperinsulinemic–euglycemic clamp, the TyG index does not require insulin measurement, is inexpensive, and is highly reproducible, making it suitable for large-scale clinical and epidemiological use. In recent years, the TyG index has been increasingly recognized as a marker…

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile